The global isothermal nucleic acid amplification technology (INAAT) market size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period. Market growth is largely driven by factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT. On the other hand, the wide usage and reliance on PCR is a major factor restraining the growth of this market.
The major players in the INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US). These players have adopted various growth strategies such as product launches, acquisitions, agreements, partnerships & collaborations, and expansion to increase their presence in the global INAAT industry.
To know about the assumptions considered for the study download the pdf brochure
Grifols (Spain) Grifols is the leading player in the global INAAT market owing to its technologically advanced platforms and associated INAAT product offerings. The company offers several nucleic acid testing instruments and assays for blood screening at blood banks, laboratories, and hospitals. Grifols primarily focuses on product launches, mergers & acquisitions, and expansions to enhance its market position. For instance, the company secured US FDA approval for two assays for Babesia and Zika virus over the last two years. The company also has a strong sales and distribution network that allows it to market its products across the globe. Being an innovation-centric company, Grifols mainly focuses on developing new instruments, reagents, and services that will help it to maintain its market share.
Hologic (US) Hologic is one of the leading companies in the INAAT market. Its molecular infectious disease panels, based on INAAT technology, account for a significant share of its diagnostics product mix. With a unique selling point of having a technologically advanced system (a combination of PCR and TMA technology), its systems are capable of executing higher test loads in laboratories and large & medium-sized hospitals. The company is expected to create a distinctive position in the INAAT market and command a decent market share during the forecast period owing to the continuous expansion of its INAAT assay portfolio. Over the last three years, the company launched three assays, namely, Panther Fusion AdV/hMPV/RV assay, Panther Fusion Paraflu assay, and Panther Fusion Flu A/B/RSV assay and received FDA/CE approvals for 13 assays based on the INAAT technology. With its strong product portfolio, product innovation, and extensive geographic presence, Hologic is expected to grow at a high rate in the INAAT market during the forecast period.
Isothermal Nucleic Acid Amplification Technology/INAAT Market by Product (Assay & Kit, System), Application (Infectious disease [HIV, Influenza], Blood Screening), Type (LAMP, SDA, NASBA, HDA), End User, Region - Global Forecast to 2024
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE